Sironax at SfN 2026

Nov 14–18, 2026 Washington, DC ~21k attendees Website

Sironax brings 3 presentations to SfN 2026 in Washington. Its SfN 2026 program centres on SARM1 inhibition, neuroprotection, and early safety and activity signals across neurodegenerative and nerve-injury conditions. One thread follows SIR2501 from preclinical work in ALS, glaucoma, and ischemic stroke to studies in patients with ALS and chemotherapy-related peripheral neuropathy.

Organization	SfN 2026 Attendance
S Sironax Beijing, China
Drug developers Biotechnology company developing medicines for neurodegenerative diseases.	Poster Sun Nov 15 1–5pm Part of Session PSTR091: ALS and Motor Neuron Diseases: Therapeutics Neuroprotective Effects of SIR2501, an Allosteric SARM1 Inhibitor, in Preclinical Studies of ALS, Glaucoma, and Ischemic Stroke WCC Halls A-C · Board U20 Poster Sun Nov 15 1–5pm Part of Session PSTR091: ALS and Motor Neuron Diseases: Therapeutics SIR2501, a Novel SARM1 Inhibitor, Demonstrates Favorable Safety and Early Evidence of Biological Activity in Patients With Amyotrophic Lateral Sclerosis WCC Halls A-C · Board U21 Poster Wed Nov 18 1–5pm Part of Session PSTR357: Peripheral Nerve Damage, Neuropathic Pain, and Repair SIR2501, a novel SARM1 Inhibitor, Demonstrates Favorable Safety, Predictable Pharmacokinetics, and Early Signals of Protection Against Chemotherapy-Induced Peripheral Neuropathy WCC Halls A-C · Board Z4

Organization

SfN 2026 Attendance

Sironax

Beijing, China

Drug developers

Biotechnology company developing medicines for neurodegenerative diseases.

Poster

Sun Nov 15
1–5pm

Part of Session PSTR091: ALS and Motor Neuron Diseases: Therapeutics

Neuroprotective Effects of SIR2501, an Allosteric SARM1 Inhibitor, in Preclinical Studies of ALS, Glaucoma, and Ischemic Stroke

WCC Halls A-C · Board U20

Poster

Sun Nov 15
1–5pm

Part of Session PSTR091: ALS and Motor Neuron Diseases: Therapeutics

SIR2501, a Novel SARM1 Inhibitor, Demonstrates Favorable Safety and Early Evidence of Biological Activity in Patients With Amyotrophic Lateral Sclerosis

WCC Halls A-C · Board U21

Poster

Wed Nov 18
1–5pm

Part of Session PSTR357: Peripheral Nerve Damage, Neuropathic Pain, and Repair

SIR2501, a novel SARM1 Inhibitor, Demonstrates Favorable Safety, Predictable Pharmacokinetics, and Early Signals of Protection Against Chemotherapy-Induced Peripheral Neuropathy

WCC Halls A-C · Board Z4

Instantly find 20 buyers from Sironax

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with the Society for Neuroscience. Organization details are derived from SfN’s published exhibitor list, its Neuroscience Meeting Planner and each organization’s own website. Submit a correction